Drug Profile
IBI 323
Alternative Names: Anti-LAG-3/PD-L1; Anti-LAG-3/PD-L1 bispecific antibody; IBI-323Latest Information Update: 14 Apr 2023
Price :
$50
*
At a glance
- Originator Innovent Biologics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Solid tumours
Most Recent Events
- 14 Apr 2023 Phase-II clinical trials in Solid tumours (IV), prior to April 2023 (Innovent Biologics pipeline, April 2023)
- 16 Jun 2021 Phase-I clinical trials in Solid tumours (First-line therapy or greater, Recurrent, Late-stage disease, Metastatic disease, Combination therapy) in China (IV) (NCT04916119)
- 16 Jun 2021 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Recurrent, Late-stage disease, Metastatic disease, Monotherapy) in China (IV) (NCT04916119)